scholarly journals Linezolid Induced Thrombocytopenia: A Case Report

2021 ◽  
Vol 11 (05) ◽  
pp. 1702-1704
Author(s):  
Harsh H. Patel ◽  
Harsha D. Makwana ◽  
Supriya D. Malhotra
Keyword(s):  
Platelet Count ◽  
Common Adverse Effect ◽  
Prolonged Treatment ◽  
Coagulase Negative Staphylococci ◽  
Baseline Platelet Count ◽  
Methicillin Resistant ◽  
Gram Positive Bacteria ◽  
Vancomycin Resistant Enterococci ◽  
Lower Body Weight ◽  
Vancomycin Resistant

Linezolid (LZD) is an antimicrobial agent with a broad spectrum of activity against virtually all clinically important Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCoNS) and vancomycin-resistant enterococci (VRE). Thrombocytopenia (TP) is a common adverse effect of Linezolid (LZD). Prolonged treatment duration, renal insufficiency, chronic liver disease, malignancy, previous vancomycin use, baseline platelet count, and lower body weight have been reported as possible risk factors for LZD-associated TP. Here, we illustrate a case of a 51-year-old male patient diagnosed with pancreatitis and urinary tract infection and was prescribed several antibiotics including Linezolid. In this case, platelets count which were initially normal started declining from day 7 of initiating Linezolid. Linezolid was withdrawn from treatment from day 9. Platelet count gradually came back to normal on day 16. This suggests reversible type of thrombocytopenia by Linezolid. This case illustrates need for careful observation of platelet count during the treatment with Linezolid. Keywords: Linezolid, Thrombocytopenia, Dechallenge

scholarly journals Use of Pristinamycin for Infections by Gram-Positive Bacteria: Clinical Experience at an Australian Hospital

2010 ◽  
Vol 54 (9) ◽  
pp. 3949-3952 ◽  
Author(s):  
A. B. Reid ◽  
J. R. Daffy ◽  
P. Stanley ◽  
K. L. Buising
Keyword(s):  
Staphylococcus Aureus ◽  
Side Effects ◽  
Epidural Abscess ◽  
Coagulase Negative Staphylococci ◽  
Methicillin Resistant ◽  
Gram Positive Bacteria ◽  
Prosthetic Joints ◽  
Vancomycin Resistant Enterococci ◽  
Vancomycin Resistant ◽  
Australian Hospital

ABSTRACT Thirty-six patients were treated with pristinamycin for 46 different microbiological isolates between April 2007 and July 2009. Pathogens included 9 methicillin-resistant Staphylococcus aureus isolates, 13 methicillin-resistant coagulase negative staphylococci, and 9 vancomycin-resistant enterococci. Sites of infections included 12 osteomyelitis cases, 10 prosthetic joints, 4 other prostheses, and 1 epidural abscess. Five patients ceased treatment due to side effects. Ten patients were cured of their infections, and 21 patients had infections successfully suppressed.

scholarly journals In Vitro and In Vivo Activities of DA-7867, a New Oxazolidinone, against Aerobic Gram-Positive Bacteria

2005 ◽  
Vol 49 (6) ◽  
pp. 2498-2500 ◽  
Author(s):  
Eun Jeong Yoon ◽  
Yeong Woo Jo ◽  
Sung Hak Choi ◽  
Tae Ho Lee ◽  
Jae Keol Rhee ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Gram Positive ◽  
Methicillin Resistant ◽  
Gram Positive Bacteria ◽  
Vancomycin Resistant Enterococci ◽  
Infection Models ◽  
Vancomycin Resistant

ABSTRACT In vitro and in vivo activities of DA-7867 were assessed against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and penicillin-resistant Streptococcus pneumoniae. All isolates were inhibited by DA-7867 at ≤0.78 μg/ml, a four-times-lower concentration than that of inhibition by linezolid. For murine infection models, DA-7867 also exhibited greater efficacy than linezolid against all isolates tested.

scholarly journals Activities of Oxadiazole Antibacterials against Staphylococcus aureus and Other Gram-Positive Bacteria

2018 ◽  
Vol 62 (8) ◽  
Author(s):  
Sara Ceballos ◽  
Choon Kim ◽  
Derong Ding ◽  
Shahriar Mobashery ◽  
Mayland Chang ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Gram Positive ◽  
Methicillin Resistant ◽  
Content Type ◽  
Gram Positive Bacteria ◽  
Vancomycin Resistant Enterococci ◽  
Vancomycin Resistant ◽  
Mrsa Strains

ABSTRACT The activities of four oxadiazoles were investigated with 210 methicillin-resistant Staphylococcus aureus (MRSA) strains. MIC50 and MIC90 values of 1 to 2 and 4 μg/ml, respectively, were observed. We also evaluated the activity of oxadiazole ND-421 against other staphylococci and enterococci and in the presence of oxacillin for selected MRSA strains. The MIC for ND-421 is lowered severalfold in combination with oxacillin, as they synergize. The MIC90 of ND-421 against vancomycin-resistant enterococci is ≤1 μg/ml.

scholarly journals Linezolid induced thrombocytopenia

2020 ◽  
Vol 9 (7) ◽  
pp. 1130
Author(s):  
P. Muthamil
Keyword(s):  
Platelet Count ◽  
Renal Transplantation ◽  
Antibiotic Prophylaxis ◽  
Rare Case ◽  
Gram Positive ◽  
Platelet Counts ◽  
Gram Positive Bacteria ◽  
Vancomycin Resistant Enterococci ◽  
Vancomycin Resistant

Linezolid, an oxazolidinone antibiotic active against gram-positive bacteria is used in the treatment of vancomycin resistant Enterococci and MRSA. It is generally tolerated except for the 32% chance of thrombocytopenia on long term usage of linezolid. A 25-year-old male after renal transplantation was administered linezolid for antibiotic prophylaxis. His platelet count dropped from 1,68,000 cells to 74,000 on day 2. The platelet counts further dropped to 58,000 on day 3, followed which linezolid was withdrawn. His platelet improved to 88,000 on day 5 following withdrawal of linezolid. Though we are vigilant about thrombocytopenia on long term usage of linezolid, here we report a rare case of linezolid induced thrombocytopenia within 2 days of starting the antibiotic. This necessitates the increased vigilance on linezolid usage. Platelet count needs to be monitored as early as the start of treatment with linezolid.

scholarly journals Quinupristin-Dalfopristin Resistance among Gram-Positive Bacteria in Taiwan

2000 ◽  
Vol 44 (12) ◽  
pp. 3374-3380 ◽  
Author(s):  
Kwen-Tay Luh ◽  
Po-Ren Hsueh ◽  
Lee-Jene Teng ◽  
Hui-Ju Pan ◽  
Yu-Chi Chen ◽  
...  
Keyword(s):  
Antimicrobial Agents ◽  
Animal Husbandry ◽  
Coagulase Negative Staphylococci ◽  
Gram Positive ◽  
In Vitro Susceptibility ◽  
Methicillin Resistant ◽  
Gram Positive Bacteria ◽  
Vancomycin Resistant ◽  
Viridans Group Streptococci

ABSTRACT To understand quinupristin-dalfopristin resistance among clinical isolates of gram-positive bacteria in Taiwan, where this agent is not yet available for clinical use, we evaluated 1,287 nonduplicate isolates recovered from January 1996 to December 1999 for in vitro susceptibility to quinupristin-dalfopristin and other newer antimicrobial agents. All methicillin-susceptible Staphylococcus aureus (MSSA) isolates were susceptible to quinupristin-dalfopristin. High rates of nonsusceptibility to quinupristin-dalfopristin (MICs, ≥2 μg/ml) were demonstrated for the following organisms: methicillin-resistant S. aureus (MRSA) (31%), coagulase-negative staphylococci (CoNS) (16%),Streptococcus pneumoniae (8%), viridans group streptococci (51%), vancomycin-susceptible enterococci (85%), vancomycin-resistantEnterococcus faecalis (100%), vancomycin-resistantEnterococcus faecium (66%), Leuconostoc spp. (100%), Lactobacillus spp. (50%), andPediococcus spp. (87%). All isolates of MSSA, MRSA,S. pneumoniae, and viridans group streptococci were susceptible to vancomycin and teicoplanin. The rates of nonsusceptibility to vancomycin and teicoplanin were 5 and 7%, respectively, for CoNS, ranging from 12 and 18% for S. simulans to 0 and 0% for S. cohnii and S. auricularis. Moxifloxacin and trovafloxacin had good activities against these isolates except for ciprofloxacin-resistant vancomycin-resistant enterococci and methicillin-resistant staphylococci. In Taiwan, virginiamycin has been used in animal husbandry for more than 20 years, which may contribute to the high rates of quinupristin-dalfopristin resistance.

scholarly journals Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin

2005 ◽  
Vol 49 (10) ◽  
pp. 4210-4219 ◽  
Author(s):  
Tatiana Bogdanovich ◽  
Lois M. Ednie ◽  
Stuart Shapiro ◽  
Peter C. Appelbaum
Keyword(s):  
Active Component ◽  
Serial Passage ◽  
Coagulase Negative Staphylococci ◽  
Low Frequencies ◽  
Methicillin Resistant ◽  
Gram Positive Bacteria ◽  
Antistaphylococcal Activity ◽  
Amoxicillin Clavulanate ◽  
Resistant Strains ◽  
Vancomycin Resistant

ABSTRACT Ceftobiprole (formerly BAL9141), the active component of the prodrug BAL5788 (ceftobiprole medocaril), is a novel cephalosporin with expanded activity against gram-positive bacteria. Among 152 Staphylococcus aureus isolates, including 5 vancomycin-intermediate and 2 vancomycin-resistant strains, MIC50 and MIC90 values for ceftobiprole were each 0.5 μg/ml against methicillin-susceptible strains and 2 μg/ml against methicillin-resistant strains. Against 151 coagulase-negative staphylococci (including 4 vancomycin-intermediate strains), MIC50 and MIC90 values were, respectively, 0.125 μg/ml and 1 μg/ml against methicillin-susceptible and 1 μg/ml and 2 μg/ml against methicillin-resistant strains. Teicoplanin was less active than vancomycin against coagulase-negative strains. Linezolid, quinupristin-dalfopristin, and daptomycin were active against all strains, whereas increased MICs for amoxicillin-clavulanate, cefazolin, minocycline, gentamicin, trimethoprim-sulfamethoxazole, levofloxacin, rifampin, mupirocin, fusidic acid, and fosfomycin were sometimes observed. At 2× MIC, ceftobiprole was bactericidal against 11 of 12 test strains by 24 h. Prolonged serial passage in the presence of subinhibitory concentrations of ceftobiprole failed to select for clones with MICs >4 times those of the parents; the maximum MIC achieved for ceftobiprole after 50 passages (in 1 of 10 strains) was 8 μg/ml. Single-passage selections showed very low frequencies of resistance to ceftobiprole irrespective of genotype or phenotype; the maximal ceftobiprole MIC of recovered clones was 8 μg/ml.

Sign in / Sign up

Export Citation Format

Share Document